Recent Company News

• 04:13 AM ET May 19, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 01:01 AM ET Jun 13, 2025
  

  Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress (€1.71, 0.00)

• 02:56 AM ET May 23, 2025
  

  StreetAccount Summary - European pre-market trading update

• 01:01 AM ET May 23, 2025
  

  Innate Pharma SA announces presentation of long-term follow-up data from the Phase 2 TELLOMAK clinical trial evaluating lacutamab (€1.97, 0.00)

• 01:03 AM ET May 13, 2025
  

  Innate Pharma reports Q1 revenue €1.6M vs year-ago €6.6M (€2.01, 0.00)

• 03:03 PM ET Apr 29, 2025
  

  Innate Pharma highlights preclinical anti-tumor efficacy data of its antibody drug conjugate IPH4502 at AACR 2025 (€1.84, 0.00)

• 01:38 AM ET Apr 24, 2025
  

  Innate Pharma closes €15M investment by Sanofi (€1.80, 0.00)

• 01:09 AM ET Apr 23, 2025
  

  Innate Pharma announce review of their January 2016 Research Collaboration and License agreement with Sanofi: (€1.72, 0.00)